Key result
Low post-transplant eGFRcys/eGFRcr ratio linked to ~146% higher MACE risk.
Why the study?
A low eGFRcys/eGFRcr ratio is linked to poor outcomes, but data in kidney transplant recipients remain limited.
Does a low eGFRcys/eGFRcr ratio predict major adverse cardiovascular events, allograft loss, and mortality in kidney transplant recipients?
Cohort (n=385)
No
Does a low eGFRcys/eGFRcr ratio predict major adverse cardiovascular events, allograft loss, and mortality in kidney transplant recipients?
Effect estimate: aHR 2.46 (95% CI 1.24-4.87)
A low eGFRcys/eGFRcr ratio (<0.7) at 3 months post-kidney transplant is an independent predictor of subsequent major adverse cardiovascular events.
Should not yet change post-transplant practice; leaves open whether the ratio enhances MACE prediction beyond standard models.
Introduction A low cystatin C–based to creatinine-based estimated glomerular filtration rate (eGFR) ratio (eGFRcys/eGFRcr) is associated with poor clinical outcomes, but data in kidney transplant recipients (KTRs) remain limited. We aimed to investigate the association between low eGFRcys/eGFRcr and allograft loss, major adverse cardiovascular events (MACEs) and mortality, and to identify the reasons for such a low ratio. Methods This single-center retrospective study included KTRs with eGFRcys/eGFRcr determined 3 months posttransplant using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) and the European Kidney Function Consortium (EKFC) equations. Body composition data were obtained from a computed tomography (CT) slice at the third lumbar vertebra as follows: skeletal muscle mass index (SMI: cross-sectional muscle area divided by height squared), myosteatosis (mean muscle CT attenuation), as well as subcutaneous and visceral adipose tissue indexes. Results Among 385 KTRs, an eGFRcys/eGFRcr < 0.7 was found in 106 (27.5%) and 54 (14%) patients with the CKD-EPI and EKFC equations, respectively. A low eGFRcys/eGFRcr ratio was independently associated with MACEs whatever the equation considered (adjusted hazard ratio [aHR]: 2.46; 95% confidence interval [CI]: 1.24–4.87 for CKD-EPI, and aHR: 2.29; 95% CI: 1.11–4.72 for EKFC), but not with death or allograft loss. Using CKD-EPI equations, diabetes mellitus was associated with eGFRcys/eGFRcr < 0.7; using EKFC equations, diabetes mellitus and male sex were associated. In the 275 KTRs with available CT scan, male sex and myosteatosis were associated with low eGFRcys/eGFRcr ratio, together with low SMI for CKD-EPI equations, and diabetes mellitus for EKFC. Conclusion A low eGFRcys/eGFRcr in KTRs is associated with MACEs. Diabetes mellitus, male sex, myosteatosis, and low muscle mass could be key factors of such a low ratio.
No takes yet. Share an insight, caveat, or question.
Moryoussef et al. (2025) conducted a cohort in Kidney transplant recipients (n=385). Low eGFRcys/eGFRcr ratio (<0.7) was evaluated on Major adverse cardiovascular events (MACEs) (aHR 2.46, 95% CI 1.24-4.87). A low eGFRcys/eGFRcr ratio (<0.7) at 3 months post-transplant was independently associated with an increased risk of MACEs (aHR 2.46; 95% CI 1.24-4.87 for CKD-EPI).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: